Compare Archer-Daniels-Midland Co (ADM) vs Davita Inc (DVA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Archer-Daniels-Midland Co vs Davita Inc — how do they compare? Archer-Daniels-Midland Co trades at $79.98 (market cap $37.69B), while Davita Inc trades at $231.13 (market cap $15.04B). The key difference: Archer-Daniels-Midland Co is far larger — about 2.5× Davita Inc's market cap, and Archer-Daniels-Midland Co pays a 2.66% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| ADM | DVA | |
|---|---|---|
Market Cap | $37.69B | $15.04B |
Sector | Consumer Staples | Health |
52-Week High | $84.11 | $235.71 |
52-Week Low | $53.54 | $103.87 |
Enterprise Value | $47.72B | $27.59B |
Dividend Yield | 2.66% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADM trades at $78.20, up 1.84% recently, with a bullish technical signal from moving averages and a consensus analyst price target of $78.00. The company has beaten EPS estimates for three consecutive quarters, though revenue has declined from $101.6B in 2022 to $80.3B in 2025. Net cash flow improved to $1.58B in 2025, reversing negative trends from prior years, while the stock shows a P/E of 34.79 and P/S of 0.47, indicating mixed valuation signals.
Outlook is cautiously optimistic with strong cash flow and earnings beats, but risks include declining revenue margins and competitive pressures. The stock offers value characteristics with a low P/S ratio, yet investors face headwinds from narrowing profit margins and global trade volatility in agricultural markets.
DaVita (DVA) trades at $234.31, showing modest daily decline but maintaining strong momentum near 52-week highs. The stock exhibits bullish technical signals with positive moving averages, though RSI levels suggest potential overbought conditions. Fundamentally, revenue growth continues with $13.64B in 2025, while net margins of 5.65% reflect steady profitability. Recent news highlights DVA's expansion in kidney care delivery and AI-driven scheduling improvements, positioning the company for continued growth in specialized healthcare services.
Investment outlook remains positive with analyst consensus favoring Buy ratings (39%) and price targets averaging $211. Key opportunities include expanding kidney care services and operational efficiencies, while risks involve high debt levels (65.55% debt-to-asset ratio) and healthcare regulatory pressures. Current valuation metrics (P/E 22.71, P/S 1.24) appear reasonable given growth prospects, though the stock trades above consensus targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Archer-Daniels-Midland Co
Archer-Daniels Midland is a major processor of oilseeds, corn, wheat, and other agricultural commodities. Additionally, the company owns an extensive network of logistical assets to store and transport crops around the globe. ADM also runs a nutrition business that focuses on both human and animal ingredients. The company is also a large producer of corn-based sweeteners, starches, and ethanol.
Read more on ADM →About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →
